Related Experiment Video

Updated: Jun 26, 2026

Characterizing Multidrug Efflux Systems in Acinetobacter baumannii Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
05:06

Characterizing Multidrug Efflux Systems in Acinetobacter baumannii Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System

Published on: January 5, 2024

Inhibitors of multidrug resistant efflux systems in bacteria

Barbara Zechini1, Ilaria Versace

  • 1Aurelia Hospital - Division of Internal Medicine, Rome, Italy. bzechini@tiscali.it

Recent Patents on Anti-Infective Drug Discovery
|January 20, 2009
PubMed

Insights

Multidrug resistance efflux pumps (MDR) are a major challenge in bacterial infections. Efflux pump inhibitors (EPIs) show promise in restoring antibiotic effectiveness by blocking these resistance mechanisms.

Area of Science:

  • Microbiology
  • Pharmacology
  • Biochemistry

Background:

  • Antibiotic resistance is a growing global health crisis.
  • Multidrug resistance (MDR) efflux pumps are key contributors to bacterial resistance in Gram-positive and Gram-negative bacteria.
  • These pumps can expel various antibiotics, leading to MDR phenotypes.

Purpose of the Study:

  • To review families of MDR efflux pumps.
  • To discuss the progress in the clinical application of efflux pump inhibitors (EPIs).
  • To highlight recent patents concerning EPIs.

Main Methods:

  • Literature review of scientific publications.
  • Analysis of patent databases for efflux pump inhibitors.
  • Focus on different classes of MDR efflux pumps and their inhibitors.

Main Results:

  • EPIs are promising therapeutic agents that can restore antibiotic activity.
  • Combinations of EPIs and antibiotics are expected to increase intracellular antibiotic concentrations.
  • EPIs may decrease intrinsic bacterial resistance, reverse acquired resistance, and reduce the emergence of resistant strains.

Conclusions:

  • EPIs represent a vital strategy to combat antibiotic resistance.
  • Further research and clinical trials are needed to fully realize the potential of EPIs.
  • The development of novel EPIs and their combination therapies is crucial for future infectious disease management.

More Related Videos

In vitro Investigation of the MexAB Efflux Pump From Pseudomonas aeruginosa13:40

In vitro Investigation of the MexAB Efflux Pump From Pseudomonas aeruginosa

Published on: February 17, 2014

Visualization of Bacterial Resistance using Fluorescent Antibiotic Probes08:23

Visualization of Bacterial Resistance using Fluorescent Antibiotic Probes

Published on: March 2, 2020

Related Concept Videos

Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Antimicrobial Proteins01:23

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...